MarginsXMarginsX
Home › Markets › Health Care › SCLX

Scilex Holding Company (SCLX)

SCLX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.25
-12.59% on the day
Market cap
$10.6M
Nano cap
Revenue · 2025
$30.3M
-46.5% on 2024
Net income · 2025
-$374.1M
-1236.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1820190/000119312526151455/0001193125-26-151455-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSCLX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001820190
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$30.3M
Net income-$374.1M
Operating income-$346.0M
Net margin-1236.4%
Operating margin-1143.7%
Revenue growth-46.5%
Cash$5.0M
Total assets$365.0M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
0.4 months
$566K cash at June 30, 2026
Share count, 1 year
-24.0%
2025-08-08 to 2026-08-10 · +24.2% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
-$2.8M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued. 3."
10-Q 2026-08-14
Cash and burn$566K cash; operating cash flow -$4.3M a quarter.Report 2026-06-30
Shares outstanding8,493,000 (2026-08-10); 6,955,697 a year earlier; 149,055,371 three years earlier. 1y figure adjusted for splits (1.606-for-1 overall); 3y figure adjusted for splits (1-for-21.793 overall).Cover page 2026-08-10
Reverse splits, 3 years1; latest 1-for-35 on 2025-04-15Source 2025-04-15
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-06-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBPM LLP, Walnut Creek, California, United States; changed auditors 3 times in 24 months8-K 4.01 2024-12-06
Late filings, 12 months2 NT noticesNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $2.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$7.6M-$115.0M-$6.7M$566K$80.8M$31.6M10-Q 2026-08-14
Q1 2026
2026-03-31
$8.6M-$45.6M-$1.1M$3.4M$80.8M$33.9M10-Q 2026-05-20
Q4 2025
2025-12-31
$4.8M-$46.1M-$17.5M$5.0M$105.7M$30.3M10-K 2026-04-10
Q3 2025
2025-09-30
$10.6M-$257.8M$8.2M$878K$45.7M$40.4M10-Q 2025-11-14
Q2 2025
2025-06-30
$9.9M-$44.0M$7.0M$4.1M$39.9M$44.2M10-Q 2026-08-14
Q1 2025
2025-03-31
$5.0M-$26.1M$6.0M$5.8M$39.4M$50.7M10-Q 2026-05-20
Q4 2024
2024-12-31
$14.9M-$6.5M$2.5M$3.3M$35.7M$56.6M10-K 2026-04-10
Q3 2024
2024-09-30
$14.4M-$4.4M$5.1M$77K$99.0M$55.2M10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-06-02
Latest annual report10-K2026-04-10
Latest quarterly / interim10-Q2026-08-14
Latest current report8-K2026-09-29
Latest proxyDEFA14A2026-05-05

Source: SEC EDGAR submissions feed, 742 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-15.9%
1 month-50.3%
3 months-78.8%
Year to date-81.2%
1 year-87.1%
From 52-week high-89.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
SCLXWScilex Holding Company Warrant$0.0263

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ALGSAligos Therapeutics Inc.$1.66-20.95%$10.4M
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
TCRXTScan Therapeutics Inc.$0.1451-9.65%$9.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier